Compass Therapeutics Inc (CMPX) - News Archive

In the rapidly evolving field of oncology, biopharmaceutical companies are continuously striving to break new ground and deliver innovative therapies to patients confronting cancer. Compass Therapeutics, Inc. (Nasdaq: C...

BOSTON, Jan. 08, 2025 — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company focused on the development of antibody-based therapeutics for various oncology-related diseases, has provided...

Compass Therapeutics Strengthens Leadership Team Amid Clinical Progress and Financial ChallengesBOSTON, Dec. 10, 2024 — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company focused on de...

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company specializing in oncology, continues to advance its research portfolio despite facing significant financial hurdles. At the 39th Socie...

Compass Therapeutics Completes Patient Enrollment in COMPANION-002: A Landmark Achievement in Biliary Tract Cancer Research BOSTON, Aug. 6, 2024 In a significant advancement in the realm of oncology, Compass Therapeutic...

Compass Therapeutics Appoints Dr. Thomas Schuetz as President and CEO, Marking a Significant Transition in LeadershipBy Boston, May 28, 2024 - Compass Therapeutics, Inc. (Nasdaq: CMPX), a renowned clinical-stage biophar...

Compass Therapeutics Presents Phase 1 Data for CTX-471, a Promising CD137 Agonist Antibody for Patients with Progressive Disease After PD-1/PD-L1 InhibitorsCompass Therapeutics, a clinical-stage biopharmaceutical compan...

Compass Therapeutics, Inc. (CMPX), a clinical-stage, oncology-focused biopharmaceutical company, has announced a significant milestone in its ongoing development of antibody-based therapeutics aimed at treating a variet...

At the annual meeting of the American Association for Cancer Research (AACR) held on April 9, 2024, in San Diego, California, Compass Therapeutics, Inc., a clinical-stage biopharmaceutical firm focused on oncology, show...

CTX-8371, a fully-human, tetravalent bispecific antibody, stands out due to its unique mechanism-of-action which entails dual blockade of PD-1 and PD-L1 as well as cleavage of cell surface PD-1. By targeting both PD-1 a...

Compass Therapeutics Provides Corporate Update: Promising Progress in Oncology-focused Biopharmaceutical DevelopmentBOSTON, Jan. 05, 2024 Compass Therapeutics, a clinical-stage biopharmaceutical company specializing in...